BioNTech
absolute frequency of genes selected for vaccination across trials the long tail of individual targets trials | BioNTech
Company
Deck Type
Sector
Industry
Deck date
June 2022
Slide
26 of 156
Related slides by other companies
Avenue Therapeutics
IPO
October 2022
safety and efficacy has been demonstrated in two phase trials in over patients | Avenue Therapeutics
AstraZeneca
Results
November 2024
dilated | AstraZeneca
AstraZeneca
Results
November 2024
solid | AstraZeneca
OKYO Pharma
Results
June 2023
phase trial start in patients announced on may | OKYO Pharma
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights